Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 21, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	329	406	111	191	199	415
Market Cap Growth	231.39%	266.57%	-41.93%	-4.16%	-52.07%	54.10%
Enterprise Value	278.09	350.6	62.95	155.92	142.68	357.51
Last Close Price	1.32	1.67	0.50	1.09	1.17	2.45
PS Ratio	22.27	27.89	11.66	21.32	13.54	95.65
PB Ratio	6.11	9.11	1.41	3.01	2.71	4.50
P/TBV Ratio	5.85	8.63	1.28	2.97	2.71	4.37
P/FCF Ratio	-	-	-	-	308.06	-
P/OCF Ratio	-	-	-	-	187.92	-
EV/Sales Ratio	18.82	24.09	6.63	17.43	9.70	82.36
EV/FCF Ratio	-	-	-	-	220.86	-
Debt / Equity Ratio	0.03	0.04	0.02	0.03	0.04	0.02
Debt / FCF Ratio	-	-	-	-	6.03	-
Net Debt / Equity Ratio	-0.95	-1.20	-0.58	-0.51	-0.74	-0.60
Net Debt / EBITDA Ratio	1.38	1.49	2.17	1.35	2.48	1.15
Net Debt / FCF Ratio	2.26	2.75	1.91	1.11	-83.56	2.32
Asset Turnover	0.13	0.13	0.09	0.08	0.10	0.03
Quick Ratio	6.65	4.99	3.47	2.02	3.06	2.32
Current Ratio	6.89	5.20	3.65	2.14	3.16	2.37
Return on Equity (ROE)	-133.30%	-105.30%	-26.73%	-32.07%	-32.37%	-46.52%
Return on Assets (ROA)	-33.95%	-29.94%	-20.05%	-20.31%	-15.42%	-34.84%
Return on Invested Capital (ROIC)	-75.26%	-61.68%	-36.03%	-39.19%	-31.63%	-66.59%
Return on Capital Employed (ROCE)	-37.22%	-36.54%	-23.56%	-26.35%	-19.40%	-43.24%
FCF Yield	-	-	-	-	0.32%	-
Buyback Yield / Dilution	-11.32%	-14.95%	-15.94%	-1.69%	-3.22%	-9.64%
Total Shareholder Return	-11.32%	-14.95%	-15.94%	-1.69%	-3.22%	-9.64%

Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q